Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiyanping for Acute Bronchitis
NCT03132623Phase 4Unknown
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Xiyanping injection + antibiotic in acute bronchitis (2 arms), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoint: Cured Rate at 7 days. Status: unknown.
02
Drugs
Xiyanping injection + antibiotic
03
Conditions
acute bronchitis
Beyond the preview
Go deeper on NCT03132623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132623.